麻将创始人李贺:Overseas Pharmaceutical’s First BFC Financing Roadshow
|Time：2017-05-18 08:47:26 Form： Writer：|
贵阳雀友麻将机维修 www.bcmfs.tw On May 18, 2017, Dr. Gilbert Wen, CEO of Overseas Pharmaceutical, attended the investment conference organized by BFC and made our first financing roadshow.
In the past year alone, Overseas Pharmaceutical had many first-time experiences. After the last round of financing, it was the first time that we obtained the human clinical data of the new pain-relief product OPL-004. The results were promising as it acted faster and last longer than the competitor (the most commonly-used drug in the US market). It was also encouraging because for the first time, we received professional media interviews that broadcast our current status, which attracted widespread interest. It was also the first time Dr. Wen participated in a formal investment financing roadshow, the first time we introduced our clinical trial data publicly, and the first time we presented our complete product development plan. Furthermore, this BFC roadshow also marked the start of the current round of financing.
The BFC financing roadshow received recognition from a number of well-known investment companies and investors afterwards. The announcement of the approval of advanced formulation category II new drugs by the CFDA led the investment market to the development of new products based on these advanced formulations. Overseas Pharmaceutical aims to be an international specialty pharmaceutical company focusing on oral controlled-release technologies for the development of second-generation products for the 505 (b)(2) regulatory pathway in the US.
This round of financing will be mainly focused on the completion of three NDA products approved by the FDA/CFDA, the production of five generic drugs that would be approved by the FDA/CFDA, and the construction of the commercial production GMP area.